Apolipoprotein B is associated with metabolic syndrome in Chinese families with familial combined hyperlipidemia, familial hypertriglyceridemia and familial hypercholesterolemia.
There is a paucity of data concerning the metabolic syndrome (MetS) in families with familial combined hyperlipidemia (FCHL), familial hypertriglyceridemia (FHTG), familial hypercholesterolemia (FH) and normolipidemic families in China. This study investigated the prevalence of MetS in these families and explored potential factors relevant to MetS. We recruited 70 families with 560 individuals > or = 20 years of age, including 43 FCHL families with 379 individuals, 3 FHTG families with 30 individuals, 16 FH families with 102 individuals and 8 normolipidemic families with 49 individuals. The definition of MetS is determined using modified criteria of National Cholesterol Education Program substituting body mass index for waist circumference. MetS is identified in 60.7% of FCHL patients and 71.4% of FHTG patients. The prevalence of MetS in family members is 36.7% for FCHL, 33.3% for FHTG, 17.6% for FH and 16.3% for normolipidemic families, with an odds ratio (OR) of 2.97 (95% CI 1.29-7.07, P=0.007) in FCHL families compared with normolipidemic families. Apolipoprotein B (apoB) is associated with MetS by multiple logistic analysis with an OR of 1.05 (1.03-1.07, P<0.001) in FCHL families, OR of 1.26 (1.03-1.55, P=0.026) in FHTG and OR of 1.07 (1.01-1.12, P=0.014) in FH families, independent of variables including age, gender, apolipoprotein A1, and low density lipoprotein cholesterol. Apolipoprotein A1 provided an OR of 0.95 (0.94-0.97, P<0.001) in FCHL families and OR of 0.94 (0.90-0.97, P=0.011) in FH families, but neither in FHTG nor in normolipidemic families (both P>0.05). Thus, apoB may be regarded as a relevant factor in the assessment of MetS in FCHL, FHTG and FH families. However, this finding needs to be verified by prospective studies in diverse ethnicities and warrants additional studies to elucidate possible mechanisms linking apoB to MetS.
Pei
Wei-dong
WD
Center for Heart Failure, Division of Cardiology, Cardiovascular Institute and Fu Wai Heart Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. pei_weidong@yahoo.com.cn
Sun
Yu-hua
YH
Lu
Bin
B
Liu
Qun
Q
Zhang
Chao-yang
CY
Zhang
Jian
J
Jia
Yu-he
YH
Lu
Zong-liang
ZL
Hui
Ru-tai
RT
Liu
Li-sheng
LS
Yang
Yue-jin
YJ
D000328:Adult; D000368:Aged; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood*; D044466:Asian People; D002681:China / Q000453:epidemiology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000235:genetics; D006950:Hyperlipidemia, Familial Combined / Q000150:complications; D006949:Hyperlipidemias / Q000150:complications* / Q000235:genetics*; D015228:Hypertriglyceridemia / Q000150:complications / Q000235:genetics; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D008875:Middle Aged; D016017:Odds Ratio; D015995:Prevalence
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B